OncoMethylome to Use BioTrove's Nanoplates to Develop Cancer Biomarkers | GenomeWeb
NEW YORK (GenomeWeb News) — OncoMethylome will use BioTrove’s OpenArray PCR screening technology to develop gene-methylation cancer biomarkers, BioTrove said today.
 
Terms of the multi-year supply agreement call for BioTrove to provide its OpenArray nanoplates and instruments to help OncoMethylome study and develop DNA methylation-based biomarkers, BioTrove said.
 
OncoMethylome focuses on detecting cancer cells and using PCR tests to predict their response to treatments.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.